ESMO-EANM ADVANCED COURSE PROGRAMME

DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF NUCLEAR MEDICINE IN ONCOLOGY

Essen, Germany 6-7 May 2025

CO-CHAIRS: Alessandra Gennari, Italy

Ken Herrmann, Germany

SPEAKERS: Eva Compérat, Austria

Wolfgang Fendler, Germany Laura Graven, The Netherlands Viktor Grünwald, Germany Jolanta A. Krajewska, Poland Michael Nader, Germany Marianne E. Pavel, Germany Ursula Vogl, Switzerland

LEARNING OBJECTIVES

- To get an updated analysis of the diagnostic and therapeutic applications of nuclear medicine in oncology
- To provide a knowledge of principles of both nuclear medicine modalities and systemic oncologic therapies in advanced trainees and specialists in oncology and nuclear medicine
- To provide an educational framework for in-depth analysis of the combined diagnostic/therapeutic strategies (theranostics) in oncology and scientific interaction between oncology and nuclear medicine experts
- To foster interdisciplinary exchange and collaboration in both nuclear medicine imaging and nuclear medicine treatment applications

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland

Email: courses@esmo.org

www.esmo.org



Tuesday, 6 May 2025

09:00-09:10	Welcome and introduction
10'	Welcome and Learning Objectives Introduction Alessandra Gennari, IT and Ken Herrmann, DE
09:10-10:50	Session 1 - Introduction to theranostics and systemic therapies Chairs: Alessandra Gennari, IT and Jolanta A. Krajewska, PL
20'	Definitions and therapeutic concepts of therapeutic radionuclides Ken Herrmann, DE
20'	Regulatory challenges in the development of theranostics Michael Nader, DE
20'	Radioiodine therapy and systemic therapy for thyroid cancer Jolanta A. Krajewska, PL
20'	Molecular imaging for prognostication and prediction of response Alessandra Gennari, IT
20'	Discussion
10:50-11:20	Coffee break
11:20-12:20	Workshop session
	Workshop session where clinical cases are presented by speakers with interactive questions and discussion with the audience
Workshop 1	
Workshop 1 12:20-13:20	audience Thyroid malignancies
	Thyroid malignancies Ken Herrmann, DE and Jolanta A. Krajewska, PL
12:20-13:20	Thyroid malignancies Ken Herrmann, DE and Jolanta A. Krajewska, PL Lunch Session 2 - NETs as role model for theranostics
12:20-13:20 13:20-14:40	Thyroid malignancies Ken Herrmann, DE and Jolanta A. Krajewska, PL Lunch Session 2 - NETs as role model for theranostics Chairs: Ken Herrmann, DE and Marianne E. Pavel, DE Overview NET: Epidemiology, disease specific characteristics and challenges
12:20-13:20 13:20-14:40 20'	Thyroid malignancies Ken Herrmann, DE and Jolanta A. Krajewska, PL Lunch Session 2 - NETs as role model for theranostics Chairs: Ken Herrmann, DE and Marianne E. Pavel, DE Overview NET: Epidemiology, disease specific characteristics and challenges Laura Graven, NL PRRT in NET: What is the standard?
12:20-13:20 13:20-14:40 20' 20'	Thyroid malignancies Ken Herrmann, DE and Jolanta A. Krajewska, PL Lunch Session 2 - NETs as role model for theranostics Chairs: Ken Herrmann, DE and Marianne E. Pavel, DE Overview NET: Epidemiology, disease specific characteristics and challenges Laura Graven, NL PRRT in NET: What is the standard? Wolfgang Fendler, DE Systemic therapies for NETs (other than PRRT)

15:10-16:50 Session 3 - Expanding theranostics to prostate cancer Chairs: Laura Graven, NL and Ursula Vogl, CH 20' Biology in advanced prostate cancer with a special focus on PSMA across the disease spectrum (primary tumour, upregulation with AR targeted therapies, heterogeneity etc) Eva Compérat, AT 20' Treatment landscape in advanced prostate cancer Ursula Vogl, CH How to make best use of PSMA RLT in advanced prostate cancer (Status May 2025) 20' Ken Herrmann, DE 20' Future of PSMA RLT outside of prostate cancer Viktor Grünwald, DE 20' Discussion and Conclusion of Day 1 19:00 Networking Dinner

Wednesday, 7 May 2025

9:00-12:30 Workshop sessions

Workshop sessions where clinical cases are presented by speakers with interactive questions and discussion with the

audience

60' Workshop time

Workshop 2 How to build and run a theranostic unit

Laura Graven, NL and Ken Herrmann, DE

Workshop 3 NET theranostics

Wolfgang Fendler, DE and Laura Graven, NL

11:00-11:30 Coffee break

Workshop 4 Prostate cancer RLT: Selection and monitoring of patients on treatment

Alessandra Gennari, IT and Ursula Vogl, CH

12:30-13:00 Conclusion & Farewell

Alessandra Gennari, IT and Ken Herrmann, DE

13:00-14:00 Lunch